NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
11 trialsNCT02002598 2024-09-19
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Phase 1/2 Terminated
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT01177683 2023-10-06
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT04762745 2021-02-21
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Unknown
NCT02477215 2020-10-22
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1/2 Completed
NCT01049945 2020-02-11
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00916058 2019-06-04
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT01484626 2018-07-10
BVRD
Loyola University
Phase 1/2 Terminated
NCT00920855 2012-10-04
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown